Zealand Pharma enters USD 200m financing agreement
With a financing agreement entailing up to USD 200m with private investment firm Oberland Capital, biotech firm Zealand Pharma wants to invest in its clinical pipline.
by christopher due karlsson, translated by daniel pedersen
On Tuesday, Zealand Pharma announces a seven-year financing agreement worth up to USD 200m with private investment firm Oberland Capital, as reported in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
